Sonnet BioTherapeutics has received a patent from the European Patent Office (EPO) for its fully human albumin binding (F H AB) technology. The patent, Albumin Binding Domain Fusion Proteins No ...

EPO grants Sonnet EU Patent No. EP3583125 B1 for Fully Human Albumin Binding (FHAB®) domain fusion proteins, expanding global IP protection. Sonnet BioTherapeutics Holdings, Inc. announced that ...

Albumin is the most abundant protein in the circulation. Its main physiologic function is to maintain colloid osmotic pressure. Better understanding of albumin's other physiologic functions has ...

Its Fully Human Albumin Binding (FHAB) technology utilizes a single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its pipeline ...

Session: Poster Session B Abstract title:Combination immunotherapy with an albumin-binding interleukin-12 fusion protein that extends cytokine half-life, targets the tumor microenvironment, and ...

Aptamers are single-stranded DNA or RNA molecules with unique 3D structures that allow for specific binding to a wide variety of ions and molecules. Due to their unique properties, aptamers have been ...

This pigment is then reduced to form the "unbound" bilirubin, which rapidly binds to albumin. However, this binding of unconjugated bilirubin can be influenced by decreases in albumin, changes in ...

Sonnet BioTherapeutics has received a patent from the European Patent Office (EPO) for its fully human albumin binding (F H ...